Answers are grounded in this paper and cite their sources.
Evidence review demonstrates improved lung function and reduced exacerbations with ensifentrine in COPD, highlighting its potential as a targeted dual PDE3/4 inhibitor.
Ensifentrine is a novel inhalational phosphodiesterase (PDE)3 and PDE4 inhibitor which improves bronchodilation and decreases inflammatory markers by acting locally on the bronchial tissue, with minimal systemic effects. Both preclinical and clinical trials have demonstrated benefits of this therapy, including improvement in lung function and reduction in exacerbations. This therapy is currently under review by the US Food and Drug Administration with a decision expected in 2024.
No takes yet. Share an insight, caveat, or question.
Faruqi et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: